Type 2 diabetes is one of the most common complex diseases, of which considerable efforts have been made to unravel the pathophysiological mechanisms. Recently, large-scale genome-wide association (GWA) studies have successfully identified genetic loci robustly associated with type 2 diabetes by searching susceptibility variants across the entire genome in an unbiased, hypothesisfree manner. The number of loci has climbed from just three in 2006 to approximately 70 today. For the common type 2 diabetesassociated variants, three features have been noted. First, genetic impacts of individual variants are generally modest; mostly, allelic odds ratios range between 1.06 and 1.20. Second, most of the loci identified to date are not in or near obvious candidate genes, but some are often located in the intergenic regions. Third, although the number of loci is limited, there might be some population specificity in type 2 diabetes association. Although we can estimate a single or a few target genes for individual loci detected in GWA studies by referring to the data for experiments in vitro, biological function remains largely unknown for a substantial part of such target genes. Nevertheless, new biology is arising from GWA study discoveries; for example, genes implicated in b-cell dysfunction are over-represented within type 2 diabetes-associated regions. Toward translational advances, we have just begun to face new challenges -elucidation of multifaceted (i.e., molecular, cellular and physiological) mechanistic insights into disease biology by considering interaction with the environment. The present review summarizes recent advances in the genetics of type 2 diabetes, together with its realistic potential. (J Diabetes Invest,
INTRODUCTION
Genetic, environmental and demographic factors, and their interaction, determine an individual's risk for type 2 diabetes; its heritability has been estimated as approximately 25% 1 . Despite considerable concerted efforts over the past 15 years, it is only in the past 5 years that substantial progress has been made in identifying genetic variants robustly associated with type 2 diabetes, largely as a result of technological advances 2 
.
In particular, the advent of genome-wide association (GWA) studies involving several thousands of samples has facilitated this progress. This approach is to search for susceptibility variants across the entire genome in an unbiased, hypothesis-free manner.
The alleles or mutations responsible for rare monogenic forms of diabetes, including maturity onset diabetes of the young (MODY), were relatively easily identified through familybased linkage analyses 3 . These discoveries then led to molecular diagnostics of the diseases with demonstrable prognostic and therapeutic relevance. Although similar approaches have been applied to common forms of type 2 diabetes, the multifactorial nature has rendered the identification of genetic variants an enormous challenge. In consideration of its low penetrance, it was proposed that association analyses in large unrelated sample sets should be more powerful in susceptibility gene discovery for type 2 diabetes than family-based linkage approaches 4 . The association signal can be detected only if one examines the causal variant itself or a nearby marker with which it is tightly correlated; therefore, researchers were obliged to direct their attention to particular candidate gene variants of interest until the advent of GWA studies. Among a number of candidate genes thus interrogated, common coding variants in PPARG 5 and KCNJ11/ABCC8 6 were shown to be associated with type 2 diabetes. In 2006, without prior knowledge of biology, TCF7L2 was first discovered to be a susceptibility gene after systematic association analysis across a 10.5-Mb region of previously reported linkage
In the present article, the evidence in favor of a genetic basis for type 2 diabetes, focusing specifically on the DNA sequence variants that have been implicated in risk predisposition and the assumed clinical implications of genomics, are reviewed.
DISCOVERY OF SUSCEPTIBILITY GENE VARIANTS FOR TYPE 2 DIABETES
Largely through GWA studies, the number of loci robustly implicated in type 2 diabetes risk; that is, those that have attained a genome-wide significance level (P < 5 9 10 -8
) and also have been repeatedly validated in independent samples, has climbed from just three -PPARG, KCNJ11/ABCC8 and TCF7L2 -in 2006 to approximately 70 today (Table 1) .
GWA studies are based on the principle of linkage disequilibrium (LD) at the population level. LD is the phenomenon in which alleles of two different loci (or genes) occur together more often than would be predicted by chance, indicating that the two alleles are physically close on the DNA strand. LD is created by evolutionary forces, such as mutation, drift and selection, and is broken down by recombination. A set of single nucleotide polymorphisms (SNPs) and mutations in strong LD tend to be inherited together by forming haplotypes. On carrying out GWA studies, we normally assay not all SNPs, but a subset of SNPs that can be chosen by considering the LD structure in a particular chromosomal region. If the pattern and strength of LD between the SNPs and mutations in the target region are similar, and the causal variants are commonly present among different populations (or different ethnic groups), the association in question is detectable at the SNP markers across the populations.
For the common type 2 diabetes-associated variants, three features have to be noted. First, genetic impacts of individual variants or loci are generally modest; that is, allelic odds ratios (ORs) for type 2 diabetes are mostly in the range between 1.06 and 1.20, apart from several loci including TCF7L2 (Figure 1 ). This reflects the necessity of a large sample size in meta-analysis to expose variants of smaller effect and more extreme risk allele frequency. Collectively, the most strongly associated variants at individual loci are estimated to explain approximately 10% of familial aggregation of type 2 diabetes 15 . Second, most of the variants identified to date are not in or near obvious candidate genes, but some are often located in the intergenic regions. This leads to the difficulty in estimating causal transcript; that is, the transcript responsible for mediating the effect of the associated variants, according to the location of association signals as discussed later. Third, although the number of variants is limited, there might be some population specificity in type 2 diabetes association. This has to be carefully interpreted by considering several possibilities; for example, the lack of power as a result of insufficient sample size and cross-population differences in LD structure 34 . Although the majority of common variants have a consistent effect on the risk of type 2 diabetes across multiple ethnic groups 35 , some variants appear to exert more pronounced genetic effects in specific ethnic groups; for example, the association at KLF14 is prominent in Europeans 15, 36 , but not in East 20 and South 19 Asians. Notably, it has been reported that most of the risk alleles for type 2 diabetes loci share a consistent pattern of decreasing frequencies along human migration from sub-Saharan Africa to East Asia 37 . Such differential frequencies are hypothesized to be caused by the promotion of energy storage and usage appropriate to environments and inconsistent energy intake.
Along with the GWA meta-analyses in individual populations, 'transethnic' meta-analysis is currently being carried out, and will allow for a better chance to show novel susceptibility loci and pathophysiological pathways of type 2 diabetes, and might also facilitate the fine mapping of common causal variants by utilizing ethnic differences in LD structure 38 .
OVERLAP OF ASSOCIATION BETWEEN TYPE 2 DIABETES AND GLYCEMIC MEASURES
GWA studies have also identified a number of genetic variants influencing glycemic measures (Tables S1-S3 ). When we focused on genome-wide significant (P < 5 9 10
) association signals, we found that they partially overlapped between type 2 diabetes 9-26 and the glycemic measure traits -fasting glucose and insulin/homeostatic model assessment (HOMA)-B (a parameter reflecting b-cell function) and glycated hemoglobin (HbA 1c ) levels in the non-diabetic population 12, [27] [28] [29] [30] [31] [32] ( Figure 2 ). As has been pointed out 39 , common variants associated with fasting plasma glucose levels do not necessarily influence the risk of type 2 diabetes and, by contrast, those associated with type 2 diabetes do not necessarily influence normal variation in fasting plasma glucose levels (48%, 11 of 23 loci overlapped), suggesting that a different set of genes influence physiological and pathophysiological variation in glucose homeostasis. Furthermore, from the viewpoint of disease mechanism and classification, of interest is the fact that there is some disparity in the list of associated loci between type 2 diabetes and fasting insulin/HOMA-B (45%, 9 of 20 loci overlapped), and between type 2 diabetes and HbA 1c levels (38%, 5 of 13 loci overlapped). In the latter case, more than half of the detected loci likely influence HbA 1c levels through a non-glycemic pathway, erythrocyte biology (e.g., iron homeostasis) 31 .
TRANSITION FROM ASSOCIATION SIGNAL TO CAUSAL MECHANISM Most loci associated with type 2 diabetes map to regulatory or intergenic regions of the genome, and in many cases the causal transcript remains undetermined. Surprisingly few of the genome-wide association signals have mapped near strong biological candidates. Nevertheless, at some loci, it is inferred, based on a combination of supportive data; for example, coding variants (in particular, non-synonymous SNPs), nearby biological candidates and cis expression quantitative trait loci (cis-eQTLs), which regulate expression levels of messenger ribonucleic acid. Here, eQTLs that map to the approximate location of their gene-of-origin are referred to as cis-eQTLs. Although eQTLs can be used to identify the downstream targets that are likely to be affected by associations detected in GWA studies, they still rely on genotyping methods, and therefore point to regions of LD rather than to individual SNPs. Accordingly, independent methods for identifying SNPs that overlap regulatory elements, such as transcription factor binding sites, are required. High-throughput functional assays (e.g., ChIP-seq 40 ) can experimentally detect functional chromosomal regions, such as transcription factor binding sites, and the presence of SNPs in these regions can lead to differences in transcription factor binding between individuals 41 . Recently, the relevant experimental datasets have been generated and released to the public by the Encyclopedia of DNA Elements (ENCODE) Consortium 40 , which will help identify functional SNPs associated with type 2 diabetes and their potential causal transcript.
Although we can estimate a single or a few target genes for individual loci by referring to the data for experiments in vitro; for example, the ENCODE data, biological function remains largely unknown for a substantial part of such target genes. So far, just 17% (12 of 70 loci) have been proven to show type 2 diabetes-related phenotypes in their knock-out mice experiments in vivo (Table 2 ). Besides, three target genes -GCK, HNF1B and HNF4A -overlap with causal genes for MODY, where GCK 42 and HNF4A
43 knock-out mice show hyperglycemia and glucose intolerance, respectively. Despite significant enrichment for regulatory (and noncoding) sequence variants in disease-associated regions, there are some cases where substantial statistical and biological evidence can support particular coding sequence variants as causal. For example, the type 2 diabetes association signal on chromosome 2p23 was shown to derive from a common non-synonymous SNP rs1260326, P446L, in GCKR, which is one of 17 genes mapped to the 420-kb interval of association in tight LD 44 . In addition to the strong candidacy of GCKR in glucose metabolism, functional characterization in vitro showed that P446L could explain a mutational mechanism for the reported counterintuitive association with increased triglycerides and reduced glucose levels on 2p23.
NEW BIOLOGY ARISING FROM GWA STUDY DISCOVERIES b-Cell Dysfunction
Regarding the pathogenesis of type 2 diabetes, there has been a long-standing debate over the relative roles of insulin secretory defects and insulin resistance. In this context, of interest is the fact that a large part of the type 2 diabetes-risk loci exert their primary effects on disease risk through reduced insulin secretion rather than increased insulin resistance in the general population 15, 45 . Genes implicated in cell-cycle regulation are overrepresented within type 2 diabetes-associated regions; this is consistent with the notion that control of b-cell mass is a key component of disease risk 15 . However, when we look at genetic loci associated with proinsulin levels, there are divergent directions of association between type 2 diabetes risk and proinsulin levels 46 . Similar to the relationship between type 2 diabetes and fasting plasma glucose 39 , the loci are partially overlapped between the traits. Among the loci associated with proinsulin, three loci -TCF7L2, C2CD4A and SLC30A8 -were significantly associated with type 2 diabetes in a manner consistent with established epidemiological relationships; that is, higher proinsulin levels are associated with impaired b-cell function, insulin resistance and risk of type 2 diabetes 47, 48 . In contrast, one locus -ARAP1 -showed trait association in a counterinstinctive direction. Thus, both disproportionate elevations and reductions in proinsulin can indicate b-cell dysfunction at individual loci 46 . Efforts to show that the genes mapping close to susceptibility loci are enriched for particular pathways or processes have not been particularly rewarding so far, apart from a few instances (e.g., cell-cycle regulation) 15 . This indicates the possibility that type 2 diabetes is highly heterogeneous, and/or existing biological knowledge is as yet insufficient to capture key fundamental aspects of its pathophysiology through database search. Although it is challenging to establish the biological mechanism at each associated locus, a combination of experimental and bioinformatic approaches will help understand the broad ) association. Gene names are attached to the loci with odds ratio (OR) ‡1.2; they are not necessarily proven to be causal, but represent candidate transcripts on the basis of location and biological plausibility. Although a large part of associated loci were originally identified in populations of European descent, some were exclusively found or first reported in non-European populations, which are differentially colored in the figure. ª 2013 Asian Association for the Study of Diabetes and Wiley Publishing Asia Pty Ltd processes of disease pathogenesis by integrating a number of loci identified in the unbiased genome-wide approach.
Epigenetics
The evidence for familial aggregation of type 2 diabetes comes from a number of epidemiological studies; parental type 2 diabetes has been reported to give rise to an approximately threefold increase in disease risk in the offspring 49 . The familial aggregation might reflect epigenetic mechanisms, such as the fetal origins hypothesis 50 , in addition to genetic influences and shared family environment. As an approach to addressing this issue, Kong et al. 51 examined the impact of parental origin on disease associations in previous GWA studies and identified parental-origin-specific associations with type 2 diabetes at variants located in the known imprinted region on chromosome 11p15. Here, the allele that confers risk when paternally inherited (odds ration [OR] = 1.41, P = 4.3 9 10 ) is protective when maternally transmitted (OR = 0.87, P = 0.02) and also correlated with decreased methylation of CTCF-binding site at 11p15 51 .
A growing body of data has established that the molecular basis of metabolic programming involves DNA methylation and histone modifications 52 . To date, relatively few studies have explored the epigenetic component to the development of type 2 diabetes, with most of them focusing on the methylation status of selected C-phosphate-G (CpG) sites in candidate genes. Because of the relatively high cost and procedural complexity of epigenetic analysis, as well as tissue differences in methylation profile, there are few convincing results that support the contribution of epigenetics to disease pathogenesis at present. To make the situation intricate, it has been reported at FTO, one of the principal risk loci for obesity and type 2 diabetes, that epigenetic effects might, at least in part, be driven by underlying variation in the DNA sequence 53 . That is, methylation levels at a CpG site in the first intron of FTO were correlated with a genotype at nearby disease-associated SNPs. This could be simply regarded as a subset of genetic association signals at which the downstream effects are mediated by genotype-dependent changes in local DNA methylation. However, it remains unclear whether methylation by Insulin/ HOMA-B (20) FPG (23) HbA 1c (13) 
Figure 2 | A schematic representation of intertrait difference (or overlapping) for 41 diabetes-related trait associated loci that have been reported in meta-analyses of genome-wide association studies 12, [27] [28] [29] [30] [31] [32] . The traits include fasting plasma glucose (FPG), insulin and its related-traits (homeostasis model assessment of b-cell function (HOMA-B) and HOMA of insulin resistance), and glycated hemoglobin (HbA 1c ). Here, an associated locus is assumed to overlap between the traits when P £ 5 9 10 -8 was concordantly attained. Underlined are the loci that have shown significant (P £ 5 9 10 -8 ) association with type 2 diabetes; at three loci with asterisks -ANK1, CDKAL1 and GRB14 -variants associated with individual traits are not in linkage disequilibrium (r 2 < 0.3). Pleiotropy GWA studies of type 2 diabetes have provided substantial evidence of pleiotropy; the same variants are associated with multiple traits (Table 3) , providing clues to the common biological pathways involved. For example, at ADCY5 and CDKAL1, the birth weight-lowering allele was associated with a greater risk of type 2 diabetes 55 . This is consistent with the fetal insulin hypothesis 56 ; that is, common genetic variation influencing insulin secretion or action, both in prenatal development and adult life, could partly explain epidemiological correlations between lower birth weight and type 2 diabetes. Here, of particular note is the fact that the type 2 diabetes risk allele at CDKAL1 also showed a significant association with lower body mass index (BMI) in adult East Asians 57, 58 , indicating the possibility of sustained, reduced insulin secretion in adulthood. In this line, despite the clustering of type 2 diabetes and obesity in metabolic syndrome, the directions of association appear to be divergent at susceptibility loci. A positive correlation has been shown between type 2 diabetes risk and higher BMI for a few obesity-associated loci; for example, FTO and MC4R, whereas an inverse correlation between the traits has been found for several type 2 diabetes-associated loci including
CDKAL1

59
. This reveals further complexity in biological pathways that influence metabolic impairments.
Several studies have examined the association of type 2 diabetes variants with cardiovascular outcome, assuming some causal association between the diseases 60, 61 . A potentially shared association has been noted at a genomic region near the SRR locus, where the minor allele C of rs216172 is positively associated with coronary heart disease (CHD) risk (OR = 1.07) in the population of European-descent 62 , and the minor allele A of rs391300 is inversely associated with type 2 diabetes (OR = 0.78) in the Chinese population 13 ; two SNPs near SRR are in LD (r 2 = 0.552 in the HapMap population of European ancestry and 0.588 in the HapMap population of East Asian ancestry). At another region on chromosome 9p21 near CDKN2A/B, a significant association has been identified for CHD 62 and type 2 diabetes 15, 19, 20 , as well as several other diseases. The 9p21 region is under intense research 63 , as independent functional variants are likely to exist within this region and could be associated with individual diseases. Apart from these two loci, the results for associations between the individual diabetes-predisposing genetic variants and CHD risk appear to be inconsistent. A few recent studies, however, have shown that, when tested in aggregate using a genetic risk score, the overall genetic predisposition to type 2 diabetes is associated with an increased risk of CHD 60, 61 . In the table, we list type 2 diabetes-associated variants, whose proxy single nucleotide polymorphisms (SNPs; r 2 > 0.4) also show significant association with other traits. *In some cases, significant type 2 diabetes-association was reported only in East Asian populations, whereas the association with other trait(s) was found in populations of European-descent. †The direction of association was estimated by considering the linkage disequilbrium (LD) information on haplotypes except for two loci (C2CD4A and RASGRP1), where LD was too modest.
GWA studies have provided evidence for an interrelation between type 2 diabetes and prostate cancer 64 . Observational studies have consistently shown an inverse association between the two diseases, with meta-analysis risk ratios ranging from 0.84 to 0.91 65, 66 . In good accordance with this, one shared genomic region at HNF1B has been highlighted in GWA scan 67 , where the major allele A of rs4430796 is positively associated with prostate cancer (OR = 1.22) and inversely associated with type 2 diabetes risk (OR = 0.91). Although the biological mechanism underlying such paradoxical associations is poorly understood, it is hypothesized that in type 2 diabetes patients, metabolic status might move gradually from hyperinsulinemia to endogenous insulin deficiency, thus blunting oncogenic action of insulin in the prostate 68 . The GWA results have further indicated a direct association between diabetes risk variants other than HNF1B and prostate cancer risk plus the lack of significant evidence supporting the potential for a type 2 diabetes phenotype to mediate the genetic effect of HNF1B
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.
POTENTIAL OF TRANSLATIONAL ADVANCES
Missing Heritability
It has been argued that susceptibility loci identified through GWA studies explain only a small proportion of heritability (approximately 5-10%) for type 2 diabetes. This discrepancy, termed missing heritability 69 , has been attributed to a number of factors including insufficient survey of rare variants and structural variants, inaccuracy of current heritability estimates (e.g., inflation because of shared family environment), and epigenetics. It remains to be defined whether complex traits are truly affected by thousands of variants with small effect, but recent analysis of GWA study data using a computational technique has suggested that many hundreds of common weakly-associated variants might be sufficient to account for the majority of heritability -approximately 50% of overall trait variance for type 2 diabetes 70 , in accordance with the assumption of 'hidden' heritability 71 . Along this, given the strong interplay of genetics, epigenetics and environment, partitioning individual propensity to develop type 2 diabetes is not feasible.
Personalized Medicine
Successful applications of personalized medicine in the clinical management of diabetes patients are restricted to the rare, monogenic forms of disease. For example, it is known that MODY patients with HNF1A mutations respond particularly well to sulphonylurea treatment 72 . Similar efforts have been made for common forms of type 2 diabetes, in two principal areas of personalized medicine -molecular prediction (or diagnosis) and personalized therapy. To provide improved predictive power over conventional risk factors, genetic testing must be sensitive and specific in discriminating subjects who will develop the disease on follow up from those who will not 73 . In this line, it has been recognized that genetic variants so far identified do not substantially improve the discriminative accuracy of disease prediction based on conventional risk factors 74, 75 . Even genetic models incorporating thousands of additional putative common variants are likely to offer limited improvement 73, 76 . Although some studies have shown that molecular prediction is slightly more effective in certain patient groups, such as the young 74, 77 , the discriminative accuracy still falls short of the clinical utility at the individual level. At the group level, in contrast, risk stratification is achievable to some extent by using a genetic risk score (GRS); this is an integrated summary of genetic risk from all the different variants in the genome that GWA studies have identified as predisposing to the disease. The GRS thus calculated has the capacity to highlight patient groups at the top end of the risk distribution 78, 79 . A higher GRS was shown to be associated with indices of diminished b-cell function and incidence of diabetes during follow up, gaining predictive ability in comparison with clinical characteristics alone 78 . Furthermore, lifestyle interventions appear to be effective even among individuals at highest genetic risk 78, 80 . Therefore, it is worth testing whether targeting such high-risk groups for an earlier preventative intervention strategy is beneficial.
From the viewpoint of individual therapeutic utility, pharamacogenetic studies in common forms of type 2 diabetes have not yet achieved remarkable progress, apart from a few successes in the candidate gene approach; for example, positive associations between variation in sulfonylurea response and genotype at the ABCC8/KCNJ11 and TCF7L2 loci 81, 82 . It is assumed that individual loci affecting antidiabetes drug response exert modest effects, and hence large-scale pharamacogenetic GWA studies are required to identify novel susceptibility gene variants.
Also, in terms of clinical management, genetics of diabetic microvascular complications -retinopathy, nephropathy and neuropathy -is an issue of great interest. Although a number of suggestive loci have been nominated through candidate gene approach or GWA study 83, 84 , none have attained genome-wide significant association with the disease, partly because of the lack of statistical power. Given the substantial genetic heterogeneity, future large-scale consortium-based studies are warranted.
PERSPECTIVE
Remarkable progress has been made in the genetics of type 2 diabetes in the past 5 years, principally through GWA studies. This proceeds with the rapid technological advances in 'the era of big data', which will further enable the sequencing of entire genomes in large samples at affordable costs. We expect that a larger list of associated loci can be discovered in the next few years, thanks to unprecedented global collaboration involving different ethnic groups. Under such circumstances, we have just begun to face new challenges -elucidation of multifaceted (i.e., molecular, cellular and physiological) mechanistic insights into disease biology by considering interaction with environment 85 before clinical translation. Table S1 | List of loci regulating fasting plasma glucose level with suggestive or significant evidence for association (P < 1E-5) Table S2 | List of loci regulating insulin-related traits with suggestive or significant evidence for association (P < 1E-5) Table S3 | List of loci regulating glycated hemoglobin level with suggestive or significant evidence for association (P < 1E-5)
